Search research articles
Contact Us
Filters
Showing results (171-180 of 257) with videos related to
Page
of 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Cancer Institute
|
May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
Toni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
Cell Metabolism
|
April 15, 2014
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells
Han Xie, Jun-Ichi Hanai, Jian-Guo Ren, et al.
Cancer Cell
|
December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer
Lianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Nature Genetics
|
September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Andrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Journal for Immunotherapy of Cancer
|
November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Abhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Cancer Discovery
|
May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition
Enrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Cell
|
November 12, 2013
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors
Brooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.
Science (New York, N.Y.)
|
March 16, 2019
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
Abhishek A Chakraborty, Tuomas Laukka, Matti Myllykoski, et al.
Page
of 26
Search research articles
Search
Showing results (171-180 of 257) with videos related to
Sort By:
Page
of 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Cancer Institute
|
May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
Toni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
Cell Metabolism
|
April 15, 2014
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells
Han Xie, Jun-Ichi Hanai, Jian-Guo Ren, et al.
Cancer Cell
|
December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer
Lianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Nature Genetics
|
September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Andrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Journal for Immunotherapy of Cancer
|
November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Abhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Cancer Discovery
|
May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition
Enrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Cell
|
November 12, 2013
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors
Brooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.
Science (New York, N.Y.)
|
March 16, 2019
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
Abhishek A Chakraborty, Tuomas Laukka, Matti Myllykoski, et al.
Page
of 26